|Day Low/High||48.16 / 56.40|
|52 Wk Low/High||12.71 / 49.55|
These 'Bearish Bets' are showing both technical and quantitative deterioration.
The Cambridge, Mass.-based firm unveiled positive top-line results from its Phase 2 study of SAGE-217 in patients with moderate to severe major depressive disorder.
The Henderson, Nev.-based company said interim data from a Phase 2 study showed an objective response rate of 73%.
Proposals are having an effect ahead of afternoon announcement.
It's hard to predict when momentum will slow, but it could be time to take some profits when the market is as strong as this morning.
The indices may need a rest, but stock-pickers have an edge.
The market response to the Fed was quite extreme, although there really wasn't any major development.
If investing is like a horserace, you can change horses in the middle of the race.
Energy and consumer defensive names dominate on the bearish side.
The market is off to a tepid start after rallying for three straight days -- certainly understandable, and some profit taking should be expected as we trade up near the highs of the relatively narrow trading range that has existed throughout most of...
Here's how to lock in gains on risky small-cap biotechnology stocks.
Stocks have gotten stronger since our last update, as the S&P 500 and DJIA have joined the Nasdaq in positive territory. Oil is giving back a little of its recent gains. One can see how lower jet fuel costs are bolstering airline earnings. Fuel cost...
As always, it is my pleasure to be filling in for Doug Kass on the Daily Diary today. Earnings reports will continue to flow in as we are in the heart of first-quarter earnings seasons, which, as usual, is coming in a little better than expectations...
As always, I am happy to be standing in for Doug Kass today on the Daily Diary (this Friday from sunny Miami). It looks like it will be an up open to talk about based on early market futures. The euro is heading towards its best week in 18 months, e...